Miguel Melo
Name: Miguel Melo
E-mail: miguelm@ipatimup.pt
Extension: 
225570700
Academic Degree: Doctor of philosophy


Miguel Melo
Miguel Melo
Member of
Research Consultant of Cancer Signalling & Metabolism


Short CV
Academic background
Degree in Medicine (MD), Medical Faculty of Coimbra, Portugal (2000)
Specialist in Endocrinology-Nutrition (2008)
Postgraduate course in Biomedicine – Medical Faculty of the University of Coimbra

Former status
Invited Assistant of Medical Genetics – University Hospital of Coimbra

Current status
Endocrinologist at the Department of Endocrinology, Diabetes and Metabolism – University Hospital of Coimbra, Portugal
Head of the Molecular Study and Diagnostic Unit - Department of Endocrinology, Diabetes and Metabolism – University Hospital of Coimbra, Portugal
Invited Assistant of Endocrinology – Medical Faculty of the University of Coimbra
PhD Student – Medical Faculty of the University of Coimbra / Ipatimup

Highlights
Biomarkers of prognosis and treatment selection in differentiated thyroid carcinomas.
Radioiodine treatment of differentiated thyroid carcinomas.

Supervisor of

PI (running)

PI (closed)
First Author
 
C
IF
1. Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. The Journal of clinical endocrinology and metabolism 102: 1898-1907, 2017. [Article] 
 
2. Melo M, Cameselle-Teijeiro JM, Eloy C, Amendoeira I, Soares P, Caneiro-Gómez J, Sobrinho-Simões M
Therapeutic options Rare Tumors of the Thyroid Gland: Diagnosis and WHO Classification  107-110, 2017. [] 
 
3. Melo M, Vicente N, Ventura M, da Rocha AG, Soares P, Carrilho F
The role of ablative treatment in differentiated thyroid cancer management Expert Review of Endocrinology & Metabolism 12: 109-116, 2017. [Review] 
 
Coexistence of TERT Promoter and BRAF Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33: 667-8, 2015. [Letter] 
 
5. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. The Journal of clinical endocrinology and metabolism 99: E754-65, 2014. [Article] 
 
6. Melo M, Costa G, Ribeiro C, Carrilho F, Martins MJ, da Rocha AG, Sobrinho-Simões M, Carvalheiro M, Soares P
Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later. The Journal of clinical endocrinology and metabolism 98: 4364-72, 2013. [Article] 
 
7. Melo M, Costa G, Carrilho F, Soares P
.
 
Senior Author
 
C
IF
Send Email
From
To
Subject